The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.
 
Michael Wang
Honoraria - Abbvie; Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Bristol Myers Squibb Foundation; CAHON; Catamount Medical Education; Dava Oncology; Genmab; Janssen Research & Development; Kite, a Gilead company; Merck; MSC National Research Institute of Oncology; NIH; Nurix; OncLive/MJH Life Sciences; Pharmacyclics/Janssen; Physicans' Education Resource; Research to Practice; Scripps Health; South African Clinical Hematology Society; Studio ER Congressi
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Amphista Therapeutics; AstraZeneca; BeiGene; Bioinvent; Deciphera; Genentech; Innocare; Janssen Research & Development; Kite, a Gilead company; Lilly; Merck; Miltenyi Biomedicine; Oncternal Therapeutics; Parexel; Pepromene; Pepromene; Pharmacyclics/Janssen; VelosBio
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bioinvent (Inst); Celgene (Inst); Genentech (Inst); Genmab (Inst); Innocare (Inst); Janssen Research & Development (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); Molecular Templates (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); VelosBio (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Lilly
Research Funding - AstraZeneca; BeiGene; Janssen-Cilag; Lilly; Morphosys; Roche; Takeda
 
Marek Trneny
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche; SOBI; Swixx BioPharma; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Autolus; Bristol-Myers Squibb; Caribou Biosciences; Genmab; Gilead Sciences; Incyte; Janssen; MorphoSys; Novartis; Roche; SOBI; Takeda
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences; janssen; Roche; SOBI; Takeda
 
David Belada
Consulting or Advisory Role - Dr. Reddy's; Genmab; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda
Research Funding - Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Roche; Takeda
 
Tomasz Wrobel
Honoraria - BeiGene; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - BeiGene; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Roche; Sanofi; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Gilead Sciences; Roche; Takeda
 
Nilanjan Ghosh
Consulting or Advisory Role - Abbvie/Pharmacyclics; ADC Therapeutics; Ascentage Pharma; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Incyte; Janssen Oncology; Kite, a Gilead company; lava therapeutics; Loxo/Lilly; Novartis; Novartis; Roche/Genentech; Seagen; Syncopation Life Sciences
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Morphosys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Mary-Margaret Keating
Consulting or Advisory Role - AbbVie; Janssen; Roche
 
Tom van Meerten
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; Kite, a Gilead Company
Consulting or Advisory Role - Gilead Sciences; Janssen; Kite, a Gilead Company
Research Funding - Bristol-Myers Squibb; Celgene; Genentech
 
Rubén Fernández-Álvarez
No Relationships to Disclose
 
Gottfried von Keudell
Honoraria - AbbVie; Incyte; Merck; Pharmacyclics
Consulting or Advisory Role - AbbVie; Incyte; Merck; Pharmacyclics
Research Funding - Abbvie; Janssen; Merck; Syndax; TG Therapeutics
 
Catherine Thieblemont
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Kite/Gilead; Novartis; Roche
 
Frederic Peyrade
No Relationships to Disclose
 
Marc Andre
Consulting or Advisory Role - Abbvie; BMSi; Eli Lilly Benelux; Novartis; Roche; Takeda
Research Funding - Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Takeda
 
Marc Hoffmann
Honoraria - AstraZeneca; BeiGene; Janssen; Kite, a Gilead Company; Novartis; Pharmacyclics; TG Therapeutics
Consulting or Advisory Role - AstraZeneca; BeiGene; Janssen; Kite, a Gilead Company; Novartis; Pharmacyclics; TG Therapeutics
 
Maoko Naganuma
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Edith Szafer-Glusman
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jennifer Lin
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
James P. Dean
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jutta Katrin Neuenburg
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Constantine S. Tam
Honoraria - Abbvie; Beigene; Janssen-Cilag; Loxo/Lilly; Novartis; Pharmacyclics; Roche/Genentech
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen-Cilag (Inst)